Catalent, Inc. (NASDAQ:CTLT) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday, October 26th. The brokerage currently has a $49.00 price target on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 28.95% from the stock’s previous close.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the topic of a number of other research reports. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $39.00 price objective (up previously from $30.00) on shares of Catalent in a report on Thursday, August 31st. J P Morgan Chase & Co reissued a “buy” rating and set a $40.00 target price on shares of Catalent in a research note on Tuesday, August 29th. Needham & Company LLC reissued a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. BidaskClub raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. Finally, William Blair reiterated an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $42.11.
Catalent (NASDAQ CTLT) traded down $0.12 on Thursday, reaching $38.00. 1,035,900 shares of the company were exchanged, compared to its average volume of 919,399. Catalent has a 1-year low of $22.94 and a 1-year high of $43.39.
Catalent (NASDAQ:CTLT) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. During the same period in the prior year, the firm posted $0.16 EPS. The firm’s revenue was up 23.0% compared to the same quarter last year.
TRADEMARK VIOLATION NOTICE: “Catalent, Inc. (NASDAQ:CTLT) Lifted to Strong-Buy at Zacks Investment Research” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/catalent-inc-ctlt-upgraded-to-strong-buy-at-zacks-investment-research.html.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. increased its stake in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after purchasing an additional 65 shares in the last quarter. Stifel Financial Corp boosted its position in Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after acquiring an additional 96 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Catalent by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,909 shares of the company’s stock worth $309,000 after acquiring an additional 130 shares during the last quarter. Aperio Group LLC boosted its holdings in shares of Catalent by 0.8% in the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock valued at $810,000 after buying an additional 190 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its holdings in shares of Catalent by 2.3% in the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock valued at $356,000 after buying an additional 230 shares during the last quarter.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.